Ceftobiprole medocaril - Basilea Pharmaceutica
Alternative Names: BAL-5788; BAL-9141; Ceftobiprole; Ceftobiprole medocaril sodium; JNJ-30982081; Mabelio; RO-65-5788; Zeftera; ZEVTERA; ZevteraLatest Information Update: 20 Apr 2024
At a glance
- Originator Basilea Pharmaceutica
- Developer Avir Pharma; Basilea Pharmaceutica; Department of Health & Human Services; Hikma Pharmaceuticals; Janssen Research & Development; Janssen-Cilag; Johnson & Johnson Pharmaceutical Research & Development; Knight Therapeutics; Shenzhen China Resources Gosun Pharmaceutical
- Class Antibacterials; Cephalosporins; Skin disorder therapies; Small molecules
- Mechanism of Action Cell wall inhibitors; Peptidyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Bacteraemia; Community-acquired pneumonia; Skin and soft tissue infections
Highest Development Phases
- Marketed Community-acquired pneumonia; Nosocomial pneumonia
- Registered Bacteraemia; Skin and soft tissue infections
- Phase III Bacterial infections
- No development reported Paediatric infections
Most Recent Events
- 03 Apr 2024 Zevtera receives priority review status for Community-acquired pneumonia, skin and soft tissue infections and Staphylococcus aureus infections in USA before April 2024
- 03 Apr 2024 Eficacy data from a phase III trial for Community-acquired pneumonia released by Basilea Pharmaceutica
- 03 Apr 2024 Eficacy data from a phase III trial for Skin and soft tissue infections released by Basilea Pharmaceutica